Filing Flows › Health Care › Gossamer Bio (GOSS)
Gossamer Bio (GOSS) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Gossamer Bio (GOSS) Q2 2026 earnings results →
Q2 2026 Revenue down 20% year over year to $9.2M · 183¢ of every $1 of revenue kept as net profit · operating margin -282.2%
Gossamer Bio made $9.2M in Q2 2026 (-20% Y/Y). Operating margin -282.2%, net earnings $16.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $9.2M in Q2 2026, down 20% year over year and down 46% from the previous quarter.
Operating costs exceeded revenue by $26.1M, an operating margin of -282.2%. Total costs fell 30% while revenue fell 20%. Net earnings were $16.9M. The effective tax rate was 0.0%. Non-operating items added $43.0M, 254% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$39.4M. Non-cash charges added back $2.5M of share-based compensation. Working capital and other items used $58.8M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $9.2M | -20% | -282.2% | $16.9M | −$39.4M |
| Q1 2026 | 10-Q | May 15, 2026 | $17.0M | +72% | -264.6% | −$46.7M | −$38.7M |
| Q4 2025 | 10-K | Mar 17, 2026 | $13.8M | +47% | -333.6% | −$47.2M | −$48.3M |
| Q3 2025 | 10-Q | Nov 5, 2025 | $13.3M | +40% | -369.4% | −$48.2M | −$36.2M |
| Q2 2025 | 10-Q | Aug 5, 2025 | $11.5M | -88% | -337.4% | −$38.3M | −$47.1M |
| Q1 2025 | 10-Q | May 15, 2025 | $9.9M | — | -372.2% | −$36.6M | −$39.7M |
| Q4 2024 | 10-K | Mar 13, 2025 | $9.4M | — | -385.2% | −$33.0M | −$35.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Gossamer Bio
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, or PH, including pulmonary arterial hypertension, or PAH, and PH associated with interstitial lung disease, or PH-ILD. Our goal is to be an industry leader in, and to enhance the lives of patients living with, PH. To accomplish this goal, we have assembled a deeply experienced and highly skilled group of industry veterans, scientists, clinicians and key opinion leaders from leading biotechnology and pharmaceutical companies, as well as leading academic centers from around the world. We intend to maintain a scientifically rigorous and inclusive corporate culture where employees strive to bring improved therapeutic options to patients.
In its own words, from its 10-K, filed Mar 17, 2026.
Gossamer Bio against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -20% against the peers' median +7%. Operating margin: -282.2% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| GOSS Gossamer Bio | Q2 2026 | $9.2M | -20% | -282.2% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Gossamer Bio 10-Q on SEC EDGAR · CIK 1728117 · Pharmaceutical Preparations
More on GOSS
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results